≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Drug-induced polyneuropathy

DOID EFO Endpoint Browser PheWeb

G6_DRUGPOLY

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G62.0#
  • Hospital discharge: ICD-9 — 3576
  • Cause of death: ICD-10 — G62.0#
  • Cause of death: ICD-9 — 3576

2 out of 7 registries used, show all original rules.

410

4. Check minimum number of events

None

410

5. Include endpoints

None

410

6. Filter based on genotype QC (FinnGen only)

311

Control definitions (FinnGen only)

Control exclude
G6_POLYNEU

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
G62
Name in latin
Polyneuropathia medicamento provocata

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1549 841 700
Only index persons 1345 745 600
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.03 0.03 0.02
Median age at first event (years)
Whole population 62.86 64.41 60.97
Only index persons 63.08 64.55 61.25

-FinnGen-

Key figures

All Female Male
Number of individuals 311 165 146
Unadjusted period prevalence (%) 0.06 0.06 0.07
Median age at first event (years) 62.77 63.63 61.79

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
324
Matched controls
3240
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G62.0
ICD-10 Finland
Drug-induced polyneuropathy
4503599627370496.0
307.7
320
*
H02AB02
ATC
dexamethasone; systemic
14.2
131.5
172
239
128
Kela drug reimbursment
Cancers of female genital organs
29.3
89.0
62
26
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
150.3
86.0
88
8
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
14.5
84.4
86
79
A04AA01
ATC
ondansetron; systemic, rectal
9.5
76.6
114
175
L03AA02
ATC
filgrastim; parenteral
16.6
74.8
68
51
A03FA01
ATC
metoclopramide; systemic, rectal
7.0
68.9
180
492
ZX120
NOMESCO Finland
Intravenous
7.6
58.2
103
188
L03AA13
ATC
pegfilgrastim; parenteral
10.0
52.9
67
82
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
10.4
52.2
64
75
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
11.4
52.0
59
62
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
9.7
50.0
65
82
N02AA05
ATC
oxycodone; systemic
5.5
49.1
142
405
N03AX16
ATC
[U] pregabalin
5.0
45.1
153
492
XW000
NOMESCO Finland
Bone marrow biopsy
9.3
42.7
56
71
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
18.6
42.5
35
21
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
15.3
40.6
37
27
A04AA02
ATC
granisetron; systemic, transdermal
7.4
40.4
66
108
JN4BD
NOMESCO Finland
Extensive body CT
5.8
40.3
90
201
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
9.0
38.1
51
66
WW500
NOMESCO Finland
Blood transfusion
8.6
38.1
53
72
JN4AD
NOMESCO Finland
Body CT examination
5.1
36.1
95
243
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
11.1
31.5
35
35
A04AA55
ATC
palonosetron, combinations; systemic
8.6
30.9
42
55
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.7
30.3
64
134
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.9
29.6
39
49
L01BC06
ATC
capecitabine; oral
7.8
29.2
43
62
R50.9
ICD-10 Finland
Fever, unspecified
4.1
29.0
106
344
N06AX21
ATC
duloxetine; oral
4.7
28.2
77
200
130
Kela drug reimbursment
Malignant tumour
4.9
27.5
71
176
B01AB05
ATC
enoxaparin; parenteral
3.4
26.5
163
738
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
9.3
26.2
33
39
N03AX12
ATC
[U] gabapentin; oral
3.9
26.0
102
345
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
24.8
92
299
B01AB10
ATC
tinzaparin; parenteral
4.2
23.0
73
211
N02BF02
ATC
pregabalin; oral
5.3
22.8
51
111
WZC00
NOMESCO Finland
Treatment plan or consultation
3.1
22.6
178
910
Z51.5
ICD-10 Finland
Palliative care
4.3
22.4
66
180
WX302
NOMESCO Finland
Thoracal epidural anesthesy
6.0
22.0
42
79
G62.8
ICD-10 Finland
Other specified polyneuropathies
123.4
21.9
23
*
ZX112
NOMESCO Finland
Subcutaneous
8.5
21.6
29
37
L04AX04
ATC
lenalidomide; oral
43.1
19.8
24
6
153
Kela drug reimbursment
Lenalidomid
43.1
19.8
24
6
C56.71
ICD-10 Finland
Serous epithelial malignant tumor of the ovary
25.6
19.0
26
11
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.0
18.9
44
99
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.7
18.8
47
112
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
18.8
211
1265
WF049
NOMESCO Finland
Radiotherapy of metastasis
6.0
18.3
34
62
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
19.5
18.1
27
15
C90.0
ICD-10 Finland
Multiple myeloma
20.1
17.6
26
14
JAL30
NOMESCO Finland
Omentectomy
22.5
17.6
25
12
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
4.2
17.2
50
134
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
53.1
17.2
20
*
329
Kela drug reimbursment
Lenalidomide
67.0
16.9
19
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
4.2
16.3
47
125
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
14.6
16.3
27
20
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
15.9
66
226
XX3DW
NOMESCO Finland
Time consuming IT work
3.4
15.7
66
228
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
30.3
15.4
20
7
ZX121
NOMESCO Finland
Central venous catheter
21.3
15.3
22
11
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.6
14.6
53
166
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
14.5
154
862
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
7.1
14.2
22
33
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
14.2
148
820
8461/3-C56.9
ICD-O-3
High grade serous carcinoma of ovary
55.9
13.9
16
*
R4110
NOMESCO Finland
Physiotherapy
2.5
13.9
132
699
ZXD05
NOMESCO Finland
Urgent procedure
2.5
13.6
118
598
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
11.2
13.5
25
24
N02BF01
ATC
gabapentin; oral
3.3
13.4
57
197
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
29.8
13.1
17
6
C56
ICD-10 Finland
Malignant neoplasm of ovary
29.8
13.1
17
6
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
20.1
13.1
19
10
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
13.0
87
388
H02AB09
ATC
hydrocortisone; systemic
5.3
12.9
27
55
N03AX09
ATC
lamotrigine; oral
5.3
12.6
26
52
WW300
NOMESCO Finland
Transfer of autologic stem cells
25.5
12.6
17
7
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
3.9
12.3
39
111
A02BC02
ATC
pantoprazole; systemic
2.6
12.2
249
1813
D70.82
ICD-10 Finland
Drug-induced neutropenia
10.7
12.2
23
23
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.7
12.2
29
66
B01AB04
ATC
dalteparin; parenteral
4.8
12.1
28
62
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
12.1
114
595
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
10.2
11.9
23
24
L02BG04
ATC
letrozole; oral
3.6
11.8
41
124
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
5.8
11.8
22
40
TPH07
NOMESCO Finland
Cathetrisation of artery
2.9
11.7
61
237
ZX131
NOMESCO Finland
Intrathecal
67.5
11.7
13
*
UJF32
NOMESCO Finland
Coloscopy
2.4
11.6
112
589
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
4.8
11.2
26
58
WF003
NOMESCO Finland
Adjuvant radiotherapy
5.0
10.9
24
51
TAB00
NOMESCO Finland
Lumbar puncture
4.0
10.9
32
86
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
4.2
10.8
30
77
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
9.0
10.7
22
26
Z3226
NOMESCO Finland
Physiotherapist
2.4
10.7
88
429
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
14.9
10.6
17
12
M04AA01
ATC
allopurinol; systemic
2.8
10.6
59
237
1XX02, ,
NOMESCO Finland
113.5
10.5
11
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.1
10.3
48
174
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
24.3
10.3
14
6
J05AB11
ATC
valaciclovir; oral
2.6
10.3
68
298
A41.9
ICD-10 Finland
Sepsis, unspecified
4.9
10.2
23
50
PJD63
NOMESCO Finland
Laparoscopic dissection of aortic lymph nodes
41.4
10.0
12
*
ZYC01
NOMESCO Finland
Remote contact by phone
3.4
9.9
37
117
N06AX16
ATC
venlafaxine; oral
2.7
9.9
62
264
ZXE30
NOMESCO Finland
More than five and less than seven hours
3.8
9.9
31
87
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
3.5
9.9
35
107
WX402
NOMESCO Finland
General anaesthesia
2.3
9.8
100
533
WW200
NOMESCO Finland
Immunization
5.5
9.8
19
36
L04AX06
ATC
pomalidomide; oral
56.7
9.7
11
*
ZX080
NOMESCO Finland
Image guided radiotherapy
5.3
9.7
20
40
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
9.5
9.7
19
21
A05AA02
ATC
ursodeoxycholic acid; oral
10.5
9.6
18
18
TPH04
NOMESCO Finland
Cathetrisation of vein
2.3
9.6
95
499
WW402
NOMESCO Finland
Leucoferesis
102.9
9.5
10
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.9
9.4
21
45
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.8
9.2
21
46
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.6
9.2
31
92
J01DB01
ATC
cefalexin; oral
2.7
9.1
277
2234
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
9.1
134
821
393
Kela drug reimbursment
Pomalidomide
37.8
9.1
11
*
1507
Kela drug reimbursment
Pomalidomide
37.8
9.1
11
*
ZXE00
NOMESCO Finland
One hour or less
2.1
9.1
148
941
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
19.3
9.0
13
7
H02AB06
ATC
prednisolone; systemic
2.0
9.0
172
1157
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
24.8
9.0
12
5
ZXE20
NOMESCO Finland
More than three and less than five hours
2.5
8.9
67
311
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
9.0
8.9
18
21
L01BB02
ATC
mercaptopurine; oral
11.2
8.9
16
15
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.4
8.8
72
347
L03AA14
ATC
lipegfilgrastim; parenteral
7.3
8.7
20
29
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
8.7
153
996
R4190
NOMESCO Finland
Nutritional therapy
3.4
8.6
33
106
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
3.8
8.6
27
76
L28
ICPC
Limited function/disability (L)
2.3
8.6
82
423
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
5.1
8.5
18
37
1XX32, ,
NOMESCO Finland
92.4
8.5
9
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
13.2
8.4
14
11
N04BC05
ATC
pramipexole; oral
3.0
8.3
39
142
JEA00
NOMESCO Finland
Appendectomy
3.5
8.3
29
88
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
9.3
8.1
16
18
WF004
NOMESCO Finland
Palliative radiotherapy
6.9
8.0
19
29
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.0
7.9
107
629
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.1
7.9
87
473
Z2446
NOMESCO Finland
Social worker
2.8
7.9
41
158
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
7.3
7.9
18
26
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
7.3
7.9
18
26
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.9
7.8
38
141
N02AX02
ATC
tramadol; systemic, rectal
1.9
7.8
156
1051
Z2221
NOMESCO Finland
Medical doctor
2.0
7.7
103
603
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
9.2
7.6
15
17
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
10.4
7.6
14
14
A04AD12
ATC
aprepitant; systemic
6.2
7.5
19
32
JAH00
NOMESCO Finland
Laparotomy
4.2
7.5
20
50
LAF16
NOMESCO Finland
Excision of uterus, adnexes and lymph nodes for treatment of ovarian cancer
13.8
7.4
12
9
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.8
7.3
38
146
J01MA12
ATC
levofloxacin; systemic
2.2
7.3
73
381
Z85.6
ICD-10 Finland
Personal history of leukaemia
+∞
7.3
7
*
Z63.7
ICD-10 Finland
Other stressful life events affecting family and household
4.5
7.3
18
42
Z3231
NOMESCO Finland
Registered nurse
2.0
7.3
116
719
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
2.9
7.3
36
135
FM2CE, ,
NOMESCO Finland
6.8
7.2
17
26
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
30.8
7.2
9
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
9.1
7.1
14
16
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
14.2
6.9
11
8
ZX114
NOMESCO Finland
Intramuscular
7.0
6.9
16
24
WB401
NOMESCO Finland
Simple antibody therapy of primary tumour
9.6
6.8
13
14
GD1AD
NOMESCO Finland
Thorax CT examination
2.9
6.8
34
128
WZC30
NOMESCO Finland
Teaching
2.1
6.7
71
378
ZXC96
NOMESCO Finland
Robot assisted procedure
5.7
6.7
18
33
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
3.0
6.7
31
112
J05AB01
ATC
aciclovir; systemic
2.0
6.7
85
485
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.0
6.6
19
50
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
4.3
6.6
17
41
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
3.4
6.6
24
75
8461/3-C57.0
ICD-O-3
High grade serous carcinoma of fallopian tube
71.2
6.4
7
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
3.7
6.4
20
56
JN4CD
NOMESCO Finland
Very extensive body CT
3.7
6.4
20
56
127
Kela drug reimbursment
Transplant complication
6.8
6.4
15
23
HAC20
NOMESCO Finland
Total mastectomy
3.6
6.4
21
61
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.5
6.3
42
183
D39.10
ICD-10 Finland
Tumor of uncertain or unknown nature in the ovary without histology
7.3
6.3
14
20
WC401
NOMESCO Finland
Simple antibody therapy of local recurrence of tumour                  
+∞
6.3
6
*
N05CD07
ATC
temazepam; oral
2.4
6.3
44
197
3AA13, ,
NOMESCO Finland
27.2
6.3
8
*
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
27.2
6.3
8
*
WX2DD
NOMESCO Finland
Low-dose CT of skeleton in whole body
27.2
6.3
8
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
6.2
53
258
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
6.5
6.2
15
24
115
Kela drug reimbursment
Breast cancer
2.6
6.2
38
160
LCD00
NOMESCO Finland
Hysterectomy
3.6
6.1
20
58
GA4AT
NOMESCO Finland
Cathetrisation of pleural cavity with ultrasound guidance
10.3
6.1
11
11
JAP00
NOMESCO Finland
Freeing of adhesions in the peritoneal cavity
10.3
6.1
11
11

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
41
39
11.89
38.31
1.3
1.6
—
—
—
0
0
98
266
4.85
34.55
11.2
3.1
64.68
66.39
g/l
1.44
91
251
97
280
4.52
31.35
1.6
1.5
—
—
—
0
0
34
36
10.43
29.35
5.8
4.1
34.98
37.25
%
0.30
34
36
102
325
4.12
28.62
7.0
4.2
4.32
21.25
ug/l
0.71
85
271
266
1597
4.72
28.46
20.9
6.9
9.74
11.70
umol/l
4.39
259
1519
237
1321
3.96
28.11
16.1
5.6
34.40
35.58
g/l
2.44
226
1244
37
54
7.61
24.73
2.9
1.9
—
—
—
0
0
27
28
10.43
23.54
5.3
2.7
—
—
—
0
0
270
1756
4.23
22.98
41.1
10.7
3.49
4.07
e9/l
4.88
249
1503
124
525
3.21
21.68
7.1
2.2
29.79
29.22
s
0.61
124
512
71
213
3.99
21.16
12.1
2.1
—
—
—
0
0
192
1051
3.03
21.09
7.4
3.5
2.35
2.36
mmol/l
0.63
183
946
106
416
3.30
20.95
7.3
4.0
1.67
1.78
%
0.65
98
386
169
865
2.99
20.95
10.2
4.5
—
—
—
0
0
86
297
3.58
20.83
1.7
1.5
—
—
—
0
0
27
34
8.57
20.32
1.1
1.4
—
—
—
0
0
28
38
7.97
19.82
6.1
4.0
1130.95
1115.25
e6/l
0.02
21
32
114
482
3.11
19.70
13.8
7.1
1.05
1.11
mmol/l
1.52
105
448
114
499
2.98
18.33
3.0
2.7
2.33
2.31
g/l
0.13
107
460
86
320
3.30
18.30
6.2
3.5
71.69
70.10
e9/l
0.11
50
241
190
1094
2.78
17.99
24.8
7.2
—
—
—
0
0
172
964
2.67
16.84
4.8
2.6
53.84
66.93
u/l
1.13
161
892
223
1425
2.81
16.70
14.1
12.5
1.21
1.23
inr
0.21
198
1168
35
72
5.33
16.57
4.7
1.5
—
—
—
0
0
230
1498
2.85
16.51
19.1
7.3
1.21
1.21
mmol/l
1.24
219
1384
243
1635
2.94
16.26
20.2
8.2
1.20
1.21
mmol/l
1.97
213
1434
213
1345
2.70
16.07
5.8
2.9
—
—
estimate
—
0
0
297
2258
4.78
16.01
22.5
8.3
89.16
86.14
u/l
0.50
291
2122
43
109
4.40
15.88
16.0
1.4
8.73
10.43
g/l
1.83
37
101
46
123
4.19
15.84
15.1
1.5
3.64
3.99
g/l
0.25
40
116
46
123
4.19
15.84
15.1
1.5
3.94
4.35
g/l
1.92
40
116
40
97
4.56
15.61
3.6
2.2
12.30
23.81
iu/l
1.77
26
67
33
69
5.21
15.32
1.7
1.8
96.34
106.76
au/ml
0.17
17
24
60
199
3.47
15.15
1.7
1.4
—
—
—
0
0
40
100
4.42
15.01
3.6
2.1
7.53
7.44
u/l
0.01
23
68
85
351
2.93
14.83
1.5
1.5
—
—
—
0
0
90
386
2.84
14.62
9.6
3.6
7.42
8.09
umol/l
0.11
79
341
18
5
37.96
14.59
10.0
10.4
—
—
—
0
0
22
13
18.04
14.51
4.5
1.5
—
—
—
0
0
167
975
2.47
14.30
6.3
2.6
—
—
—
0
0
22
33
7.08
14.21
7.2
4.0
513.20
522.31
e6/l
0.02
15
26
251
1784
2.81
13.90
14.2
5.6
6.47
6.68
mmol/l
1.08
244
1711
233
1602
2.62
13.72
23.5
7.2
0.57
0.59
e9/l
0.50
210
1338
33
77
4.66
13.46
1.5
1.7
—
—
—
0
0
235
1630
2.61
13.45
23.6
7.2
1.67
2.01
e9/l
2.48
212
1406
232
1608
2.56
13.16
23.6
7.2
0.04
0.04
e9/l
1.81
210
1345
38
102
4.09
12.97
19.8
3.0
25.60
2.11
ratio
0.51
25
53
220
1496
2.47
12.88
25.4
7.4
9.82
8.83
%
3.56
211
1407
24
44
5.81
12.79
7.9
4.0
—
—
—
0
0
213
1431
2.43
12.76
37.3
12.7
0.00
0.00
e9/l
0.65
196
1149
22
37
6.31
12.76
16.6
2.4
—
—
—
0
0
219
1490
2.45
12.75
25.3
7.3
0.69
0.68
%
0.09
210
1397
25
27
9.94
12.73
3.5
3.1
0.66
1.04
g/24h
0.58
20
20
219
1494
2.44
12.61
25.2
7.2
2.68
2.90
%
0.75
210
1401
221
1519
2.43
12.43
25.2
7.3
27.51
28.52
%
0.57
212
1440
139
786
2.35
12.32
8.2
2.9
320.55
343.78
umol/l
1.38
131
686
164
996
2.31
12.28
11.6
4.0
7.39
7.40
ph
1.18
126
694
233
1647
2.48
12.18
27.0
7.6
0.17
0.20
e9/l
2.42
209
1403
162
982
2.30
12.15
33.4
7.1
—
—
—
0
0
218
1503
2.38
11.96
24.6
7.2
56.33
56.26
%
0.03
213
1432
28
63
4.77
11.91
2.8
1.7
—
—
—
0
0
28
63
4.77
11.91
2.8
1.7
—
—
—
0
0
28
63
4.77
11.91
2.8
1.7
—
—
—
0
0
28
63
4.77
11.91
2.8
1.7
—
—
—
0
0
15
5
31.33
11.75
30.3
23.0
0.46
0.39
umol/l
—
15
5
43
137
3.47
11.45
5.7
3.2
26.00
1902.54
u/ml
1.06
38
114
77
343
2.63
11.36
19.4
9.0
—
—
—
0
0
93
459
2.44
11.03
2.5
2.0
—
—
—
0
0
122
686
2.25
10.64
5.8
1.9
2.28
1.36
mg/l
0.45
100
558
23
30
8.17
10.58
1.2
1.1
—
—
—
0
0
16
10
16.75
10.46
1.0
1.0
—
—
—
0
0
255
1936
2.49
10.45
7.4
5.0
11.57
1179.11
e6/l
—
7
38
153
948
2.16
10.41
5.9
3.7
0.31
0.39
e6/l
0.31
126
696
20
21
10.07
10.41
7.8
5.8
0.16
0.24
e9/l
0.39
13
14
23
31
7.90
10.38
7.0
4.2
146.44
143.96
e6/l
0.01
16
26
104
552
2.30
10.37
5.1
3.7
1.83
2.19
e6/l
0.23
72
277
169
1091
2.15
10.32
6.0
3.8
54.55
112.17
e6/l
0.38
143
845
27
67
4.31
10.18
13.6
1.9
—
—
—
0
0
68
304
2.57
9.86
4.1
2.3
28.16
34.74
u/l
0.85
62
250
114
640
2.21
9.85
4.1
3.3
504.89
532.31
mosm/kgh2o
0.87
102
560
192
1319
2.12
9.76
4.5
3.1
218.40
132.40
ug/l
2.00
177
1227
28
74
4.05
9.72
13.3
1.8
361.50
6.91
e6/l
0.49
22
58
15
10
15.65
9.61
1.1
1.2
—
—
—
0
0
63
275
2.60
9.58
6.0
5.0
1.53
0.88
%
0.69
30
98
127
754
2.13
9.44
4.2
2.9
3.96
4.56
e6/l
0.37
117
687
28
76
3.94
9.38
13.3
1.9
154.82
177.93
e6/l
0.05
22
60
78
384
2.36
9.13
1.4
1.6
—
—
—
0
0
59
255
2.61
9.13
5.9
5.2
0.26
0.15
%
0.44
27
78
158
1032
2.04
8.96
10.3
3.4
34.03
33.61
u/l
0.06
152
977
74
361
2.36
8.82
6.8
8.2
0.72
0.96
mmol/l
0.21
64
313
16
16
10.45
8.62
3.7
1.4
1856.87
1350.31
ml
1.35
16
16
60
269
2.51
8.59
5.8
5.6
0.19
0.08
%
0.50
27
79
24
63
4.03
8.40
1.1
1.2
—
—
—
0
0
73
364
2.30
8.24
7.1
8.2
7.41
7.41
ph
0.27
39
210
140
899
1.98
8.11
1.8
1.7
21.56
21.49
nmol/l
0.02
123
740
254
2012
2.21
8.05
6.7
4.9
—
2.71
—
0
5
176
1225
1.96
8.03
7.7
4.7
47.80
83.66
e6/l
0.90
145
875
27
80
3.59
7.99
1.4
1.9
185.55
223.56
u/ml
0.24
20
39
14
13
11.19
7.87
1.2
1.1
—
—
—
0
0
57
260
2.45
7.84
5.7
4.9
0.62
0.49
%
0.27
26
89
112
672
2.02
7.82
4.4
1.7
2.31
2.49
g/l
0.12
82
384
127
797
1.98
7.80
2.6
2.6
2.72
2.94
mg/l
0.33
116
689
38
143
2.88
7.63
40.9
13.1
1.07
1.32
mg/l
2.29
33
129
18
28
6.74
7.52
10.2
2.0
—
—
—
0
0
140
929
1.89
7.13
3.9
3.4
—
—
—
0
0
83
461
2.08
7.07
18.1
7.9
103.59
103.91
mmol/l
0.19
83
461
31
109
3.04
7.01
1.4
1.8
—
—
—
0
0
14
17
8.55
6.90
3.0
4.1
469.93
944.65
mg
0.81
14
17
18
34
5.54
6.56
1.2
1.1
—
—
—
0
0
16
27
6.18
6.39
2.1
2.8
32.74
40.14
%
—
5
14
178
1308
1.80
6.27
2.6
2.1
92.20
96.34
pmol/l
0.55
115
653
120
784
1.84
6.24
1.9
1.4
—
—
—
0
0
158
1122
1.80
6.23
2.8
2.2
—
—
—
0
0
182
1348
1.80
6.22
3.3
2.8
77.92
77.92
nmol/l
0.00
169
1211
144
1000
1.79
6.08
4.0
3.4
978.07
1214.51
ng/l
0.54
127
852
19
54
3.68
5.97
1.2
1.0
—
—
—
0
0
31
123
2.68
5.65
4.5
6.3
142.05
305.37
mg/l
1.02
20
57
19
57
3.48
5.53
1.2
1.1
—
—
—
0
0
15
29
5.37
5.46
1.2
1.2
—
—
—
0
0
69
392
1.97
5.41
26.5
6.3
1.50
1.85
mmol/l
0.34
61
329
9
8
11.53
5.32
3.6
2.8
30.89
32.25
u/l
—
9
8
9
8
11.53
5.32
4.6
1.6
—
—
—
0
0
207
1634
1.74
5.30
5.0
4.3
0.00
0.96
estimate
0.51
54
319
205
1616
1.73
5.25
5.0
4.2
69.77
0.00
estimate
0.78
57
344
70
404
1.93
5.23
26.2
6.2
7.39
7.38
ph
0.87
47
238
66
374
1.96
5.20
5.9
3.4
3.63
6.25
e9/l
1.06
58
328
65
368
1.96
5.13
1.9
1.7
—
—
—
0
0
201
1600
1.68
4.74
5.0
4.2
0.00
0.00
estimate
-0.00
55
332
52
280
2.02
4.72
3.5
2.5
7.80
13.04
nmol/l
4.22
44
259
15
35
4.44
4.69
1.3
1.9
—
—
—
0
0
155
1159
1.65
4.64
4.1
4.1
24.69
84.75
ng/l
0.73
122
890
23
88
2.74
4.50
1.8
1.1
—
—
—
0
0
10
15
6.84
4.50
1.9
2.3
—
—
—
0
0
129
929
1.65
4.42
2.6
2.2
128.14
203.57
u/l
2.18
121
884
79
502
1.76
4.29
1.8
1.7
1148.93
1219.25
nmol/l
0.24
57
375
60
353
1.86
4.19
1.4
1.3
—
—
—
0
0
222
1845
1.65
4.14
5.7
3.6
84.00
51.43
u/l
1.28
207
1720
64
386
1.82
4.13
1.3
1.3
—
—
—
0
0
14
42
3.44
4.09
5.5
1.6
4.50
6344.81
u/l
—
6
9
53
302
1.90
4.08
3.5
5.6
5.11
5.11
kpa
0.00
48
294
7
7
10.18
4.03
2.1
3.0
37.71
30.00
%
—
7
7
12
27
4.57
3.97
15.6
3.2
0.58
0.78
index
0.49
12
27
23
95
2.53
3.90
1.4
1.4
281.98
280.99
ug/g
0.01
15
56
87
583
1.67
3.87
5.6
3.9
104.31
384.98
ng/l
1.81
74
472
7
8
8.91
3.79
1.0
1.6
—
—
—
0
0
94
652
1.62
3.63
7.5
5.6
—
—
—
0
0
51
299
1.84
3.59
3.6
5.6
7.42
7.42
ph
0.12
38
243
12
32
3.85
3.42
4.2
3.3
63.55
51.52
u/ml
0.11
12
32
12
32
3.85
3.42
1.1
1.2
—
—
—
0
0
7
10
7.13
3.38
2.1
2.9
—
—
—
0
0
10
23
4.45
3.33
1.8
1.2
—
—
—
0
0
303
2807
2.23
3.26
44.5
17.1
28.60
24.61
mg/l
1.31
286
2286
12
34
3.62
3.23
1.2
1.5
—
—
—
0
0
41
238
1.83
2.99
4.1
4.6
—
—
—
0
0
267
2397
1.65
2.96
64.4
21.7
14.15
13.66
%
7.02
267
2376
29
151
2.01
2.91
1.3
1.3
—
—
—
0
0
6
9
6.77
2.88
2.3
1.8
0.61
0.61
mmol/l
—
6
9
10
28
3.65
2.80
5.2
1.4
0.20
0.14
nmol/l
—
10
14
16
66
2.50
2.75
2.3
4.5
—
—
—
0
0
44
268
1.74
2.74
4.1
5.2
98.58
73.77
ng/l
0.66
37
233
7
14
5.08
2.74
1.3
1.1
—
—
—
0
0
21
100
2.18
2.65
1.2
1.2
—
—
—
0
0
6
11
5.53
2.55
7.8
4.5
34.25
45.09
%
—
6
11
26
138
1.96
2.49
1.8
2.2
0.00
0.02
estimate
—
10
45
16
71
2.32
2.38
1.3
1.3
—
—
—
0
0
116
910
1.43
2.37
4.9
4.3
0.00
0.00
estimate
-0.00
53
320
7
17
4.18
2.37
1.3
1.1
—
—
—
0
0
37
227
1.71
2.27
4.0
5.6
—
—
—
0
0
8
197
0.39
2.26
1.0
1.4
—
—
—
0
0
5
9
5.62
2.22
1.0
1.1
—
—
—
0
0
5
9
5.62
2.22
1.0
1.0
157.00
139.78
nmol/l
—
5
9
247
2226
1.46
2.21
5.2
4.4
14.88
14.88
pmol/l
0.00
229
2025
11
43
2.61
2.10
3.3
1.9
34.09
32.72
pg
0.57
11
43
154
1289
1.37
2.09
4.6
3.7
6.10
6.19
ph
0.49
77
710
83
625
1.44
2.09
2.0
1.8
453.48
22674861.13
pmol/l
0.50
65
516
27
156
1.80
2.04
2.6
2.5
—
—
—
0
0
9
32
2.86
2.01
1.2
1.1
—
—
—
0
0
42
277
1.59
1.97
2.6
2.1
0.00
0.05
estimate
—
10
59
107
853
1.38
1.94
4.4
3.7
0.00
0.09
estimate
0.52
38
277
59
423
1.48
1.91
1.5
1.3
—
—
—
0
0
6
17
3.58
1.84
2.0
3.5
811.00
816.88
u/ml
—
6
17
54
387
1.47
1.75
1.8
1.5
—
—
—
0
0
9
36
2.54
1.75
2.4
2.1
—
—
—
0
0
28
172
1.69
1.74
1.1
1.4
—
36.03
—
0
15
58
423
1.45
1.72
1.5
1.4
824.62
533.21
titre
0.33
13
106
107
867
1.35
1.72
4.2
3.3
—
0.11
—
0
19
97
777
1.35
1.68
5.1
4.0
—
0.13
—
0
8
7
26
2.73
1.59
1.4
1.4
—
—
—
0
0
6
21
2.89
1.51
1.3
1.0
—
—
—
0
0
32
212
1.57
1.50
1.5
1.3
89.09
258.97
u/ml
1.17
27
200
127
1077
1.29
1.45
3.5
3.7
6.39
7.57
mmol/l
2.67
102
901
6
22
2.76
1.44
1.0
4.4
7.18
7.07
mmol/l
—
6
22
37
259
1.48
1.37
5.7
4.2
7.38
7.36
ph
0.16
27
178
139
1202
1.27
1.34
4.9
4.0
0.00
0.01
estimate
0.74
38
283
8
36
2.25
1.25
1.0
1.2
—
—
—
0
0
9
45
2.03
1.24
67.8
9.6
7.07
11.62
%
—
9
45
52
397
1.37
1.22
2.0
3.0
117.31
137.47
ug/g
0.23
42
321
305
2944
1.61
1.22
35.6
13.0
27.00
25.90
u/l
0.57
300
2861
8
38
2.13
1.19
1.9
1.3
—
—
—
0
0
7
30
2.36
1.13
1.1
1.1
—
—
—
0
0
7
32
2.21
1.08
1.1
1.2
—
—
—
0
0
276
2628
1.34
1.07
6.3
5.4
1.97
1.99
mu/l
0.13
253
2402
7
34
2.08
1.03
1.1
1.2
—
—
—
0
0
12
68
1.79
1.02
1.1
1.1
—
11.21
—
0
11
22
148
1.52
1.01
1.9
2.1
2.52
7.99
iu/ml
—
5
36
36
268
1.39
1.00
1.6
1.4
—
—
—
0
0
9
49
1.86
0.99
1.1
1.1
—
—
—
0
0
9
49
1.86
0.99
1.1
1.1
—
—
—
0
0
9
50
1.82
0.97
7.2
2.8
2.73
4.71
e9/l
—
9
50
6
27
2.24
0.94
1.0
1.3
—
—
—
0
0
89
1033
0.81
0.93
4.1
3.4
—
—
—
0
0
14
87
1.64
0.89
44.8
6.0
49.25
64.71
%
1.78
14
87
115
1012
1.21
0.88
3.3
3.4
35.74
49.92
mg/l
0.52
69
650
8
43
1.88
0.88
2.3
3.2
—
—
—
0
0
16
105
1.55
0.83
2.4
3.0
—
—
—
0
0
13
81
1.63
0.82
6.8
2.5
47.24
59.67
%
2.28
13
81
296
2870
1.36
0.81
31.8
14.9
—
—
—
0
0
35
270
1.33
0.80
1.2
1.3
—
—
—
0
0
15
98
1.56
0.80
1.3
1.1
—
—
—
0
0
86
744
1.21
0.78
1.3
1.5
0.91
2.23
u/ml
0.96
18
182
10
60
1.69
0.73
1.3
1.1
—
—
—
0
0
12
76
1.60
0.72
2.7
5.2
—
—
—
0
0
281
2714
1.27
0.72
5.7
5.5
4.55
4.57
mmol/l
0.13
258
2510
7
40
1.77
0.71
1.4
1.3
—
—
—
0
0
5
28
1.80
0.66
1.6
1.9
—
—
—
0
0
269
2595
1.22
0.63
5.1
4.5
1.46
1.29
mmol/l
2.77
242
2373
5
30
1.68
0.61
1.4
1.7
—
—
—
0
0
114
1034
1.16
0.59
4.1
4.1
7.94
25.68
mg/mmol
0.51
65
644
8
54
1.49
0.57
3.6
1.4
—
—
—
0
0
8
55
1.47
0.56
3.6
1.4
—
—
—
0
0
30
241
1.27
0.55
2.3
2.7
11.03
8.17
ug/l
0.20
24
216
14
192
0.72
0.54
1.3
1.3
—
—
—
0
0
7
45
1.57
0.49
5.7
1.4
—
—
—
0
0
79
708
1.15
0.48
5.1
4.1
1.02
1.02
kg/l
1.07
57
481
7
47
1.50
0.48
3.0
1.4
—
—
—
0
0
16
121
1.34
0.45
1.5
1.7
0.17
0.36
mg/l
—
10
52
9
130
0.68
0.44
1.8
2.0
—
—
—
0
0
5
31
1.62
0.43
3.2
3.0
3.82
7.33
umol/l
—
5
25
277
2704
1.17
0.41
5.6
5.3
1.39
1.46
mmol/l
2.00
251
2485
5
33
1.52
0.41
2.8
1.5
—
—
—
0
0
5
36
1.39
0.38
1.0
2.2
-1.62
0.94
mmol/l
—
5
36
45
509
0.87
0.36
1.4
1.3
4.71
8.66
u/ml
0.44
18
184
29
246
1.20
0.35
3.8
2.5
5.98
6.11
ph
0.38
22
162
6
87
0.68
0.33
1.5
1.2
0.88
0.94
g/l
—
6
87
7
54
1.30
0.30
4.0
1.4
—
—
—
0
0
7
55
1.28
0.30
4.0
1.4
—
—
—
0
0
7
55
1.28
0.30
1.7
2.9
—
—
—
0
0
7
55
1.28
0.30
4.1
1.4
—
—
—
0
0
16
130
1.24
0.29
1.4
1.3
—
—
—
0
0
8
63
1.28
0.28
2.1
1.4
—
—
—
0
0
17
141
1.22
0.26
1.6
1.6
—
—
—
0
0
274
2695
1.11
0.24
5.7
5.4
6.01
6.01
mmol/l
0.00
250
2466
280
2757
1.11
0.24
6.2
6.3
2.68
2.65
mmol/l
0.19
254
2546
5
38
1.32
0.23
1.0
1.2
—
—
—
0
0
64
595
1.09
0.23
3.2
3.2
0.90
0.76
ug/l
0.22
44
380
131
1255
1.07
0.23
2.4
1.9
1.49
1.34
mmol/l
1.07
103
1045
5
39
1.29
0.23
1.0
1.4
—
—
nmol/l
—
0
0
33
296
1.13
0.22
1.6
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
9.83
—
0
11
0
10
0.00
0.21
0.0
1.0
—
37.30
—
0
10
0
10
0.00
0.21
0.0
3.4
—
—
—
0
0
0
12
0.00
0.21
0.0
10.8
—
0.64
—
0
12
104
991
1.07
0.21
6.5
5.5
2.69
2.54
ug/l
0.06
90
898
6
48
1.25
0.20
1.2
1.1
—
—
—
0
0
271
2670
1.09
0.20
6.9
6.8
39.33
39.71
mmol/mol
0.28
248
2508
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
51
549
0.92
0.20
1.5
1.3
29.49
31.01
iu/ml
0.03
11
174
7
60
1.17
0.18
1.7
1.5
—
—
—
0
0
7
62
1.13
0.17
1.3
4.2
4.90
9.44
pmol/l
—
7
62
22
197
1.13
0.16
29.7
4.5
1.26
1.28
%
0.02
22
197
7
86
0.81
0.14
1.1
1.1
—
—
—
0
0
109
1061
1.04
0.10
4.2
3.8
—
0.80
—
0
5
21
195
1.08
0.08
31.0
4.5
0.55
0.62
%
0.63
21
195
14
128
1.10
0.07
1.1
1.1
—
—
—
0
0
8
95
0.84
0.06
1.1
1.6
—
—
—
0
0
27
284
0.95
0.06
2.4
1.8
—
—
—
0
0
10
90
1.11
0.05
13.2
10.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
8.2
—
4.92
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
139.50
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.02
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
2.01
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
17.40
—
0
5
0
6
0.00
-0.00
0.0
3.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
57.60
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint G6_DRUGPOLY and mortality.

Females

Parameter HR [95% CI] p-value
G6_DRUGPOLY 4.185 [3.26, 5.37] < 0.001
Birth year 0.996 [0.98, 1.01] 0.502

During the follow-up period (1.1.1998 — 31.12.2019), 289 out of 698 females with G6_DRUGPOLY died.

Males

Parameter HR [95% CI] p-value
G6_DRUGPOLY 2.961 [2.28, 3.84] < 0.001
Birth year 0.99 [0.98, 1.0] 0.032

During the follow-up period (1.1.1998 — 31.12.2019), 218 out of 581 males with G6_DRUGPOLY died.

Mortality risk

Mortality risk for people of age

years, who have G6_DRUGPOLY.

N-year risk Females Males
1 0.486% 0.586%
5 2.514% 3.499%
10 6.052% 8.655%
15 11.118% 16.382%
20 19.482% 27.032%

Relationships between endpoints

↥

Index endpoint: G6_DRUGPOLY – Drug-induced polyneuropathy

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data